parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in podocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 400	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7658

receipt 7666: ACTN4 in dopamine neurons, braak

power: full sample -0.13 (p 0.615, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.498, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to -0.00, sign flips 0; without severely affected donors -0.13 (p 0.615, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACTN4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7665: ACTN4 in oligodendrocytes, braak

power: full sample -0.43 (p 0.074, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.47 (p 0.050, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.42 (p 0.082, n 18). could be the mix.
skeptic: leave-one-out range -0.51 to -0.36, sign flips 0; without severely affected donors -0.43 (p 0.074, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACTN4 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts